COVID-19 vaccination: Two women worsened after ‘Kovaccin’ injection in Gurugram

During a nationwide vaccination campaign to end the corona epidemic, two people were reported to have worsened after being vaccinated in Gurugram.

According to reports, the health of an Anganwadi worker and an Asha worker has deteriorated after being vaccinated at a vaccine center in Palam Vihar, DPSG. Anandwadi worker Anandlata had difficulty breathing due to high blood pressure. During the observation, the team of doctors regained their health about an hour and a half after the drug was administered. At the same time, Asha was a workaholic. After giving birth she became normal.

RML Hospital Doctors Object ‘Kovacsin’, Learn Why

The two women were ‘Kovacsin’ at the center. Clinical trial of this vaccine is ongoing. Approval letters have been filled for people who have been vaccinated at the center. However, there are no problems with the location of the Cowshield vaccine.

‘Coveshield’ at one of the five centers and Kovacsin in one

A vaccination campaign is underway at six centers in Gurugram district and Saturday. The ‘Cowshield’ vaccine is being applied at five centers from the health center and the ‘Cowaxin’ vaccine is being given at the DPSG school in Chauma. Filling consent letters from health workers.

Notably, the world’s largest vaccination campaign against the corona virus has begun nationwide on Saturday. Prime Minister Narendra Modi on Saturday launched India’s Vaccination Campaign against Kovid-19, which is the world’s largest vaccination campaign and said it shows India’s strength.

The Prime Minister, scientists and experts who addressed the nation through a video conference before the start of the vaccination campaign have been allowed to use it only after promising the safety of ‘Made in India Vaccines’.

.

Disclaimer: The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.